Categories: Tech

CORRECTION — Innventure announces strategic investment in Accelsius by Johnson Controls

This press release was corrected to specify that Innventure’s private placement was unrelated to the strategic investment in Accelsius by Johnson Controls.

ORLANDO, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) — Innventure, Inc. (NASDAQ: INV) is pleased to announce a strategic investment in Accelsius, a provider of two-phase, direct-to-chip liquid cooling systems, by Johnson Controls (NYSE: JCI). JCI announced the transaction earlier today in a press release that can be found here.

In an unrelated transaction, Innventure also announces the closing of a private placement of Innventure common stock and warrants anchored by CastleKnight. The gross proceeds from this transaction were $9.75 million. This capital raise, along with the recently disclosed issuance to Yorkville of convertible debentures in an aggregate principal amount of up to $15 million, provides working capital to support Innventure’s ongoing business operations.

About Innventure
Innventure founds, funds, and operates companies with a focus on transformative, sustainable technology solutions acquired or licensed from multinational corporations. As owner-operators, Innventure takes what it believes to be breakthrough technologies from early evaluation to scaled commercialization utilizing an approach designed to help mitigate risk as it builds disruptive companies it believes have the potential to achieve a target enterprise value of at least $1 billion. Innventure defines ‘‘disruptive’’ as innovations that have the ability to significantly change the way businesses, industries, markets and/or consumers operate.

Media Contact: Laurie Steinberg, Solebury Strategic Communications
press@innventure.com

Investor Relations Contact: Sloan Bohlen, Solebury Strategic Communications
investorrelations@innventure.com

GlobeNews Wire

Recent Posts

Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjgrens disease

Basel, January 16, 2026 – Novartis today announced that the US Food and Drug Administration (FDA)…

3 weeks ago

Personar Appoints Former Genius Sports COO Eric Stevens as Chief Operating Officer to Scale Award-Winning Sports Technology Platform

Tuesday 13 January, 2026 LONDON – Tuesday, January 13, 2026 – Personar, the AI sports…

3 weeks ago

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans…

4 weeks ago

Secret Ingredient’s 2025: Redefining Hospitality through Story, Space and Strategy

NEW DELHI, Dec. 31, 2025 /PRNewswire/ -- Secret Ingredient, one of India's foremost food and…

1 month ago

GAC Receives Industry’s First Vehicle Data Security Management System Certificate

TIANJIN, China and GUANGZHOU, China, Dec. 31, 2025 /PRNewswire/ -- On December 24th, GAC received…

1 month ago